Does Spravato Help With Anxiety? What Patients Should Know
Anxiety and depression rarely travel alone. If you live with treatment resistant depression, there is a strong chance you also carry a heavy load of anxiety, panic, rumination, and physical tension. So when patients begin exploring Spravato as a next step in their care, one of the first questions we hear at Serenada Mental Health is whether this medication, designed for depression, might also calm the relentless anxiety that has been running in the background of their lives. It is an honest question and it deserves a careful answer.
So, does Spravato help with anxiety? The honest answer is that Spravato is not FDA approved as a primary treatment for anxiety disorders. It is approved for treatment resistant depression and for major depressive disorder with acute suicidal ideation. However, the picture becomes more interesting when you look at how depression and anxiety overlap in real patients, what the research on esketamine and anxiety is starting to show, and what clinicians in practice actually observe. In this article we will walk through the FDA approved uses of Spravato, the science of comorbid anxiety and depression, what emerging research suggests about esketamine and anxiety symptoms, and how an integrative psychiatric provider can help you think through whether Spravato belongs in your treatment plan.
What Spravato Is FDA Approved to Treat
To answer the question of whether Spravato helps with anxiety, we have to start with what the medication is actually approved to treat. Spravato, the brand name for esketamine nasal spray, received FDA approval in 2019 for adults with treatment resistant depression, defined as having tried two or more antidepressants at adequate dose and duration without meaningful relief. In 2020, the FDA expanded the approval to include adults with major depressive disorder who are experiencing acute suicidal ideation or behavior. Both approvals were granted on the basis of clinical trials that measured depressive symptoms, not anxiety symptoms, as the primary outcome.
This matters because it shapes what prescribers can and cannot promise. A psychiatric provider cannot ethically prescribe Spravato as a first line treatment for generalized anxiety disorder, panic disorder, social anxiety disorder, or obsessive compulsive disorder. Those conditions have their own evidence based treatment pathways, typically involving SSRIs or SNRIs and cognitive behavioral therapy. When Spravato is used, it is almost always because the patient also carries a diagnosis of treatment resistant depression. The anxiety question, then, is not really about whether Spravato is an anxiety medication. It is about whether treating the depression with esketamine also tends to reduce the anxiety that comes along with it.
The Overlap Between Depression and Anxiety
Understanding the relationship between depression and anxiety is essential to making sense of the question. Clinical studies consistently show that somewhere between 50 and 70 percent of adults with major depressive disorder also meet criteria for an anxiety disorder during their lifetime. This phenomenon, sometimes called anxious depression, is associated with more severe symptoms, longer episodes, higher rates of treatment resistance, and a greater risk of suicidal ideation than depression without anxiety. In other words, the two conditions are deeply intertwined in a way that makes it hard to fully separate them.
This overlap matters for the Spravato conversation because it raises an important possibility. If a patient's anxiety is partly driven by the same neurobiological processes that drive their depression, and if esketamine effectively treats the depression by acting on the glutamate system and promoting neuroplasticity, then it is reasonable to ask whether the anxiety might improve as well. The brain does not always respect the diagnostic categories we draw around it. Many patients experience anxiety as a feature of their depression rather than as a fully separate condition, and for those patients, treating the depression effectively can have meaningful spillover effects on the anxiety.
Does Spravato Help With Anxiety? What the Research Shows
Let us get to the heart of the question. Does Spravato help with anxiety according to the available research? The most accurate answer is that the evidence is promising but not yet definitive, and it comes from a few different angles.
Pooled Analyses of FDA Trial Data
When researchers have gone back and looked at the data from the pivotal Spravato trials, they have found something interesting. Although the trials were designed to measure depression outcomes, many of the patients enrolled also had significant anxiety symptoms at baseline. In post hoc analyses, patients who received Spravato alongside an oral antidepressant showed greater reductions in anxiety symptoms than those who received an oral antidepressant plus placebo. The effect was most notable in patients with high baseline anxiety, which is the very population most likely to ask whether Spravato might help them. This is not the same as a randomized trial designed to test Spravato for anxiety, but it is a meaningful signal that deserves attention.
Real World Clinical Observation
In clinical practice, providers who treat patients with Spravato regularly report that anxiety symptoms often improve alongside depressive symptoms. Patients describe a lifting of the constant background worry, a softening of the physical tension in their chest, and a greater ability to step back from catastrophic thinking. These observations are consistent with the mechanism of esketamine, which acts on the glutamate system in ways that appear to promote flexibility in neural patterns associated with both depression and anxiety. The brain circuits involved in threat detection, rumination, and mood regulation overlap significantly, and a medication that promotes neuroplasticity in those circuits may reasonably be expected to affect both kinds of symptoms.
Emerging Ketamine Research
Although this article focuses on Spravato, it is worth noting that the broader ketamine literature offers additional context. Intravenous ketamine, which is chemically related to esketamine, has been studied more extensively for anxiety related conditions, including treatment resistant generalized anxiety and social anxiety disorder. Several small studies have shown rapid reductions in anxiety symptoms following ketamine infusion. This research does not directly translate to Spravato, but it supports the broader hypothesis that NMDA receptor modulation may have anxiolytic effects, not only antidepressant effects.
When Spravato May Be Considered for Anxious Depression
Given what we have just reviewed, when does it make sense to consider Spravato for a patient whose anxiety is wrapped up with their depression? The starting point is always the FDA approved indication. Spravato is appropriate for adults with treatment resistant depression, meaning they have not responded adequately to two or more antidepressants. If that criterion is met and the patient also carries significant anxiety, the conversation about whether Spravato may help with both becomes relevant.
Spravato may be particularly worth considering when several of the following are true:
You have a confirmed diagnosis of treatment resistant depression with comorbid anxiety symptoms.
Standard anxiety treatments, including SSRIs, SNRIs, and therapy, have not produced adequate relief on their own.
Your anxiety appears to be tightly linked to your depressive episodes rather than existing as a fully separate condition.
You are motivated to engage in psychotherapy alongside the medication, since the combination tends to produce the most durable outcomes.
You have no medical contraindications to esketamine, such as uncontrolled hypertension or a history of aneurysm.
The decision is always individualized. A psychiatric provider experienced in interventional psychiatry can walk through your specific history, symptoms, and treatment goals to help you determine whether Spravato belongs in your plan. If you want to explore this further, our team at Serenada Mental Health offers comprehensive evaluations at our Georgetown and Waco clinics. You can also read more about related options in our guide to advanced treatment options for depression.
When Spravato Is Not the Right Fit for Anxiety
Just as important as knowing when Spravato may help is knowing when it is not the right path. Spravato is not appropriate as a standalone treatment for an anxiety disorder in a patient who does not also have treatment resistant depression. If you have generalized anxiety disorder, panic disorder, social anxiety disorder, or obsessive compulsive disorder without a coexisting depression diagnosis, the evidence based first line treatments remain SSRIs, SNRIs, and cognitive behavioral therapy.
Spravato is also not a replacement for the structured work of anxiety treatment. Even when esketamine reduces anxiety symptoms, the most durable outcomes come from combining the medication with psychotherapy that addresses the thought patterns, avoidance behaviors, and physiological responses that maintain anxiety. For patients whose primary concern is anxiety rather than depression, we typically begin with a thorough evaluation and a treatment plan centered on therapy and appropriate medication management. To learn more about how we approach anxiety care, see our guide on anxiety and panic disorder treatment. The right treatment is the one that fits your actual diagnosis, not the one that happens to be trending.
The Role of Therapy in Treating Anxious Depression
Whether or not Spravato becomes part of your treatment plan, therapy has a central role to play in addressing the combination of depression and anxiety. Cognitive behavioral therapy for anxiety is one of the most researched and most effective interventions available. It helps patients identify the catastrophic thought patterns that fuel anxiety, test those thoughts against reality, and gradually build more accurate and workable ways of interpreting the world. For patients whose depression is rooted in unresolved trauma, trauma focused therapies can address the underlying experiences that drive both the anxiety and the depression.
When Spravato is part of the picture, therapy becomes even more important. Esketamine opens a window of heightened neuroplasticity during which the brain is unusually receptive to new learning. The insights, skills, and perspectives developed in therapy are more likely to take hold during this window. Patients often describe breakthroughs that previously felt out of reach, a sudden ability to question long held beliefs, and a softening of the chronic self criticism that has driven both their anxiety and their depression. This is why an integrative approach that combines Spravato with structured psychotherapy tends to produce more durable outcomes than medication alone. You can read more about our overall approach on our Spravato treatment service page.
What to Expect if You Start Spravato Treatment
If you and your clinician decide that Spravato is appropriate for your treatment resistant depression, knowing what to expect can reduce anxiety about the process itself. Spravato is administered as a nasal spray in a REMS certified clinic under the direct supervision of a healthcare provider. Each session lasts approximately two hours from intake to discharge, with blood pressure and symptom monitoring throughout. The standard protocol begins with twice weekly sessions for the first four weeks, transitions to weekly sessions for weeks five through eight, and then moves to a maintenance phase with sessions every two weeks or monthly depending on your response.
During and shortly after a session, some patients experience transient dissociation, dizziness, sedation, or mild increases in blood pressure. These effects typically resolve within the two hour observation period. Patients cannot drive themselves home and must arrange for a trusted adult to transport them. At Serenada Mental Health, our treatment rooms are designed to be quiet, private, and comfortable, and our staff is trained to support patients through every step of the experience. Many patients find that knowing exactly what to expect significantly reduces the anxiety they feel leading up to their first session.
Accessing Spravato Treatment in Central Texas
For adults in Central Texas, accessing REMS certified esketamine therapy has become significantly easier in recent years. Serenada Mental Health offers Spravato treatment at both our Georgetown and Waco clinics, bringing interventional psychiatry closer to home for residents across the region. Whether you live in Georgetown, Waco, Round Rock, Temple, Belton, or the rural communities in between, qualified care is now within reach.
We accept a broad range of insurance, including Medicare, TriWest and TriCare, and ChampVA, which is particularly important for veterans and military families in our region who are disproportionately affected by treatment resistant depression and comorbid anxiety. For patients whose schedules or locations make regular in person visits challenging, our telehealth psychiatry in Texas offering extends much of the surrounding care into the home. While the Spravato doses themselves must be administered in person under clinical supervision, psychiatric follow up, medication management, and much of the psychotherapy can be delivered securely by video. This hybrid model makes integrative care more accessible for working adults, parents, and patients in rural areas.
The Bottom Line on Spravato and Anxiety
So, does Spravato help with anxiety? The most accurate answer is that Spravato is not an anxiety medication in the strict FDA approved sense, but the available research and real world clinical experience suggest that many patients with anxious depression do experience meaningful improvements in anxiety symptoms when their depression is effectively treated with esketamine. The benefit appears to be greatest in patients whose anxiety is intertwined with their depression rather than in patients with a primary anxiety disorder alone. For the latter group, evidence based treatments like SSRIs, SNRIs, and cognitive behavioral therapy remain the appropriate first line approach.
If you live with treatment resistant depression and the anxiety that so often accompanies it, the question is not really whether Spravato is an anxiety medication. It is whether treating your depression more effectively might also bring your anxiety along toward remission. For many patients, the answer is yes. The only way to know whether that is likely in your case is a thorough evaluation with a psychiatric provider who understands the nuance of comorbid anxiety and depression and who can build a treatment plan around your full clinical picture.
Take the Next Step Toward Clarity and Relief
At Serenada Mental Health, we know that navigating treatment resistant depression and chronic anxiety can feel exhausting. The questions pile up, the medication trials blur together, and the prospect of starting yet another treatment can feel daunting. Our role is to walk through those questions with you honestly, using the best available evidence and a clinical philosophy that treats you as a whole person rather than a diagnosis. Where healing begins with understanding, and where your concerns are taken seriously rather than dismissed.
Call us at (512) 612-9441 or click Book Now to schedule a comprehensive consultation at our Georgetown or Waco clinic. The clarity you have been looking for starts with a single conversation, and we would be honored to have it with you.